Due to the presence of CD30 on the surface of cancer cells, there has been considerable interest in the receptor as a target for anti-tumor biologics and cancer immunotherapy, leading to the development of targeted treatments such as the chemotherapy–CD30 antibody combination brentuximab vedotin (BV) for the treatment of Hodgkin’s and other lymphomas [6,7,8]. This evidence concerns the gene TNFRSF8 and cancer.